Who Paid My Doc
Steven Almany
Cardiovascular Disease Troy, MI Medical Doctor
NPI 1295717205 CMS profile 148840
4600 Investment Dr, Suite 200, Troy, MI 48098
General payments
$470,508
Research payments
$0
Ownership & investment interest
$431,723
Research they led as principal investigator
$11,882
Through program year 2021, Steven Almany of Troy, MI is reported in the CMS Open Payments database as having received $470,508 across 108 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $11,882 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $431,723 across 13 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $368 | 16 | |
| 2020 | General | $847 | 40 | |
| 2019 | General | $469,293 | 52 | |
| 2025 | Ownership | $13,087 | 1 | |
| 2024 | Ownership | $82,084 | 2 | |
| 2023 | Ownership | $82,084 | 2 | |
| 2022 | Ownership | $84,860 | 3 | |
| 2021 | Ownership | $87,524 | 3 | |
| 2020 | Ownership | $82,084 | 2 |
Beside peers
- Steven Almany
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Steven Almany were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Steven Almany | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $469,293 | $450 | $127–$1,392 | $163 |
| 2020 | $847 | $242 | $77–$751 | $114 |
| 2021 | $368 | $335 | $101–$1,037 | $132 |
| 2022 | $0 | $395 | $121–$1,211 | $149 |
| 2023 | $0 | $443 | $136–$1,283 | $160 |
| 2024 | $0 | $450 | $136–$1,323 | $164 |
| 2025 | $0 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
108 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Michigan
Marschall Runge
Cardiovascular Disease · Ann Arbor, MI
Jihad Mustapha
Cardiovascular Disease · Grand Rapids, MI
Vallerie McLaughlin
Cardiovascular Disease · Ann Arbor, MI
Pedro Villablanca Spinetto
Cardiovascular Disease · Detroit, MI
Stanley Chetcuti
Cardiovascular Disease · Ann Arbor, MI
David Haines
Cardiovascular Disease · Royal Oak, MI
Related records
Cardiovascular Disease in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.